# **OMEDLEY** Presentation Material for FY2023 Q2 Financial Results

Medley, Inc. August 14, 2023


# Disclaimer

### Disclaimer

In preparing these materials, Medley, Inc. ("the Company") relies upon and assumes the accuracy and completeness of all available information. This presentation may contain future assumptions, prospects and forecasts based on planning, but these forward-looking statements are based on the information that is currently available to us, and on certain assumptions that we assume to be reasonable, but the Company does not promise to achieve these. Major differences may occur between the forecast and the actual performance, including changes in economic conditions, consumer needs and user preferences; competition with other companies; changes in laws, regulations and others; and a number of other future factors. Therefore, the actual performance announced may vary depending on these various factors.



**Financial Highlights** 



Maintained a high rate of sales growth and made steady progress toward our full-year earnings targets

- Sales: JPY 6,270 million (YoY: +50%)

EBITDA margin remained at the same level as FY22 Q2 even as we continued to invest in growth

- EBITDA: JPY 2,210 million (YoY: +50%)

- EBITDA margin: 35% (FY22 Q2: 35%)

# • We raised our full-year FY2023 forecast owing to steady earnings

- Sales: JPY 19,800 million (previously: JPY 19,150 million) - Gross Profit: JPY 13,300 million (previously: JPY 13,120 million) - EBITDA: JPY 2,950 million (previously: JPY 2,260 million) - Ordinary Profit: JPY 3,000 million (previously: JPY 1,760 million) - Profit Attributable to Owners of Parent: JPY 2,000 million (previously: JPY 1,180 million)



# 1. FY2023 Q2 Results

3. Investment Highlights

2. Progress Towards Mid-Term Targets and FY2023 Forecast



# Summary of Consolidated FY2023 Q2 Results

JPY mm

# Sales

# **Gross Profit**

# **EBITDA**


**Operating Profit** 

Ordinary Profit

Profit Attributable to Owners of Parent

FY2022 Q2	FY2023 Q2	Yo
4,181	<b>6,270</b>	
3,225	4,504	
1,476	2,210	
1,328	2,040	
1,431	2,277	
999	1,525	






# **Steady Progress Toward Earnings Forecast**

Aggregate Q2 FY2023 sales made 56% progress toward our FY2023 full-year forecast, which is a higher rate of progress than usual.

**Aggregated Quarterly Sales**<sup>(1)</sup>

(JPY mm)

Q1 Q2 Q3 Q4



(1) Figures for FY2021 and earlier are based on the new revenue recognition standard.




# Maintain High Sales Growth Rate

Strong companywide sales growth of +50% YoY in Q2 FY2023.

Quarterly Sales<sup>(1)(2)</sup> (JPY mm)





(1) HR PF Business posts sales based on the hire dates of new employees.


(2) Figures for FY2021 and earlier are based on the new revenue recognition standard.






# **Continued Aggressive Investment in Growth, etc Funded by Profitable Businesses**

Although we continued to proactively invest into growth initiatives, EBITDA margin of Q2 FY23 remained at the same level as Q2 FY22. In addition, we posted another positive EBITDA quarter in the Medical PF segment.






(1) Figures for FY2021 and earlier are based on the new revenue recognition standard. (2) Total of companywide expenses not allocated to segments and inter-segment eliminations.

(3) One-time cost (JPY 100 million) for acquiring a source code to add a new function to Medical PF Business. (4) One-time cost (JPY 130 million) for acquiring EMR assets from another company.


(5) One-time office relocation costs: JPY 93 million in Q2, JPY 79 million in Q3.

### **MEDLEY**



# **Overview of Investments in Growth and Costs Associated with Business Expansion**

EBITDA margin in the HR PF segment narrowed due to an increase marketing spend. In the Medical PF segment, EBITDA margins improved despite continued investment to improve gross margin and an increase in headcount. Corporate expenseto-sales ratio also improved despite an increase in headcount.



(1) Total companywide costs and cross-segment limitations not allocated to any business segment

Main Factors Contributing to Change in Q2 EBITDA margin						
Segment	Q2 FY22	Q2 FY23	Main Fac			
HR PF	63.0%	60.7%	<ul> <li>Increase in marketing margi</li> </ul>			
Medical PF	-9.6%	0.1%	<ul> <li>Improvement in labor cost e growth</li> </ul>			

### Main Factors Contributing to Change in corporate expenses

(JPY mm) \*figures in parentheses show each cost to quarterly sales ratio

	·	
Q2 FY22	Q2 FY23	Ma
195 (4.7%)	275 (4.4%)	<ul> <li>Increased number of co</li> </ul>
177 (4.2%)	116 (1.8%)	<ul> <li>One-off decline in rent or rent paid in FY2022 owir</li> </ul>
68 (1.6%)	71 (1.1%)	<ul> <li>Hiring progressed smoo</li> </ul>
84 (2.0%)	93 (1.5%)	<ul> <li>One-off decline of costs</li> </ul>
23 (0.6%)	43 (0.7%)	• _
	195 (4.7%) 177 (4.2%) 68 (1.6%) 84 (2.0%) 23	$\begin{array}{c c c c c c c c c c c c c c c c c c c $



ain Factors

g margin (-3.7%pt)

cost efficiency owing to sales

ain Factors

orporate department employees


costs (JPY 78mm) due to double ing to office relocation

### othly

s incurred in FY2022

# (Ref.) EBITDA Margins: Results and Policies by Segment

For the HR PF Business, our basic policy is to achieve high revenue growth while maintaining our EBITDA margin. For the Medical PF Business, though we will continue to invest in our medium-term growth (as stated in our FY2022 presentation) material), we plan to improve our gross margin in order to enable high sales growth while maintaining EBITDA profitability.




Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	(
	F١	19			FY	20			FY	21			FY	2



Q4	Q1	Q2	Q3	Q4	Q1	Q2
		FY		F١	(23	

The number of customer offices and ARPU, our main KPIs, have been continuously growing and we plan to keep investing going forward. Generally, HR PF sales increases sharply in Q2, which also results in ARPU to increase.



account.



businesses. Since 4Q FY2019, customer offices using both platforms have been counted as a single customer

# **Financial Position Remains Strong**


Our financial base remains sound (capital ratio: 69.9%, D/E ratio 0.11x)

### B/S as of the End of March 2023

(JPY mm)

	Untapped LOC 2,700
	Debt 2,145
Cash and	Other liabilities 4,097
deposits 13,952	Net assets
Other assets 7,858	15,568

Capital ratio: 70.9%, D/E ratio: 0.14x



Capital ratio: 69.9%, D/E ratio: 0.11x



Debt 1,941 Other liabilities 5,328

> Net assets 17,231






### **Continued Growth in Number of Customers on Schedule** HR PF

In Q2 FY2023, we continued to make steady progress in signing on new customer offices and we currently have contracts with 317 thousand offices.

Number of Customer Offices (thousand)




Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2 FY16 FY18 FY19 FY20 FY21 FY17

(1) Ministry of Health, Labour and Welfare, Ministry of Internal Affairs and Communications, and Cabinet Office statistics



# **Recruitment System: Accelerate Direct Recruiting** with Expansion of the Pool of Registered Workers


Proactive recruitment methods are effective for hiring medical and healthcare professionals. In Q2 FY2023, our customers increased usage of our scouting functions as we expanded our pool of registered workers.





# **Online Training System: Released New Functions Using Generative Al**

We released a new function that makes use of generative AI on our online training system, JobMedley Academy. In addition, we are promoting the proactive and appropriate utilization of AI technology in order to improve internal operational efficiency, as well as our customer value proposition.



### Background behind providing new function


- JobMedley Academy features over 6,500 lecture videos
- Trainers can create unique curricula by searching and combining different lecture videos

Al-generated suggestion 2 2 **Goal Setting** Input Training Title **Goal Suggestion** User inputs a title for the Skill/knowledge acquisition User sets goals based on suggestions provided training desired goals suggested

### Impact of new function

- With the use of generative AI, trainers can more quickly and easily create training curricula tailored to the needs of individual employees
- Time required to produce training curricula reduced by approximately 75%





### **Online Training System:**

# Began providing service to home-visiting dental care providers

In addition to nursing care and disability welfare providers, we started to provide our online training system to homevisiting dental care providers. We will continue to proactively create synergies by leveraging our customer base in order to expand into other fields.

### **Development of Operations Support Systems**




(1) As of end of June 2023





Medical PF





Dental clinics

Nursing and welfare


SaaS

facilities

Sales Reached a New Historical High Medical PF

Although FY2023 Q2 customer offices and sales increased YoY, the concentration of large orders from hospitals in Q1 had a negative QoQ impact. For 2H, we expect YoY sales growth to slow down as we plan to prioritize improvements in gross margin. However, we expect sales growth to improve from FY2024 Q1.





(1) Number of customer offices = number of medical intuitions that have begun using our systems (CLINICS, Pharms, etc.) and have not cancelled or discontinued their contracts; customers using multiple systems counted as a single customer account

(2) Figures for FY2021 and earlier are based on the new revenue recognition standard




Medical PF

# Measures to Expand Number of Customers, Improve ARPU, and Streamline Operations

In Q2 FY2023, we implemented a number of measures to boost the medium- to long-term growth and profitability of the Medical PF Business. These include expanding our target customers, improving ARPU, and streamlining measures.

### Main Measures Implemented in Q2 FY2023



ics	Pharmacies	De
/IR		
ons	Conducted development aimed at strengthening functionality	Conducted of strength
ving to rs		
ner		
of		
nt of DCOMO	Joint operation of businesses with NTT DOCOMO via minacolor	Strengther C




### ental Clinics

development aimed at ening functionality

### ned integration with LINICS app

Our CLINICS app is consistently at the top of the telemedicine app rankings. We began joint operation of the app with NTT DOCOMO in December 2021 and our patient user base continues to grow.



(1) Comparison among telemedicine apps which cover insured medical treatment; Source: data.ai



# 1. FY2023 Q2 Results

# FY2023 Forecast


3. Investment Highlights

2. Progress Towards Mid-Term Targets and



# Mid-term Target: Aim to Maximize Long-term Free Cash Flow


Our management policy is to maximize long-term free cash flow, and aim to maintain high sales growth by increasing the value provided to our customers. In order to achieve sales growth, we pursue a business model focused on stable, recurring sales. Further investments will therefore be made in growth focused on maximizing the number of customers and achieving continuous ARPU growth by improving utilization rates and strengthening product lineup. In both the current mid-term targets and the next mid-term targets we will follow this policy in principle.





# (Ref.) Revision of Mid-term Target: Brought Forward Timeline for Achievement of the Goals by one year

Steady earnings progress has made it more likely that we will be able to achieve our targets in FY2024; so, in February <u>2023, we brought forward our mid-term targets by one year.</u>




FY22 FY23E FY24E FY25E FY19 FY21 FY20

Sales	(billion yen)	(billion yen)								
23bn One Year Forward	Year	Before Revision (CAGR32%)	After Revision (CAGR39%)	Sales Forecast	Actual Sales					
	2019	4.3	4.3	_	4.3					
e e e e e e e e e e e e e e e e e e e	2020	5.7	6.0	-	6.0					
	2021	7.5	8.4	-	10.4					
	2022	10.0	11.8	_	14.1					
	2023	13.2	16.4	19.1						
	2024	17.4	23.0							
	2025	23.0								




# (Ref.) Next Mid-term Plan: The General Direction

We plan to announce our next mid-term plan in February 2024 alongside our full-year FY2023 results. We are focusing on high sales growth to maximize long-term free cash flow, and will complete our review during FY2023, including our profit policy during the next mid-term target period.



Fargets of Current Mid-term Plan	The General Direction of N
February 2020 Updated in February 2023)	February 2
FY24 Brought Forward from FY25)	Around F
+39% (FY19-FY24E) *Expect to exceed target	Around +
Positive EBITDA	<b>Profit margin</b> (Positive EBITDA in a







# **Raising Our FY2023 Forecast**

We raised our FY2023 forecast due to steady progress in our business and lower-than-expected SG&A expenses even after accounting for additional contingency costs. Consequently, we now expect approximately +40% YoY sales growth.

(JPY mm)	Previous forecast (announced Feb. 14, 2023)	Revised forecast (announced Aug. 14, 2023)	Change	Main fact
Sales	19,150	19,800	+650	Mainly progre
Gross Profit	13,120	13,300	+180	Busin
EBITDA	2,260	2,950	+690	Lower SG&A
Operating Profit	1,630	2,250	+620	accou contin
Ordinary Profit	1,760	3,000	+1,240	Non-c (settle
Profit attributable to Owners of Parent	1,180	2,000	+820	receiv

### **MEDLEY**


ctors behind the change

nly as a result of steady ress made in the HR PF ness

er-than-expected A expenses even after ounting for additional ingency costs

-operating income tlement income ived, etc.)

# **FY2023 Forecast: Assumption and Progress**



	Financial Indicators		Pr
e same	<ul> <li>Sales Growth: <u>Approximately +40%</u> (FY22: +38%)</li> <li>EBITDA margin: <u>Approximately 40%</u> (FY22: 45%)</li> </ul>	•	Raise bette
job ictionality :em			progr
nlining costs es in order to ty ses ire patient	<ul> <li>Sales Growth: <u>+40% or more</u> (FY22: +32%)</li> <li>EBITDA margin: <u>Approximately 0%</u> (FY22: -8%)</li> <li>As with HR PF, priority is given to improving gross margin to enable high growth <u>with positive EBITDA.</u></li> </ul>	•	Raise foreca margi
geting mid-			
ly factored in			
rsing	<ul> <li>Bringing new nursing care related business <u>into the</u> <u>black</u></li> </ul>	•	Starte US, bi
re	<ul> <li>Test marketing costs in the USA: <u>Approximately JPY</u> <u>350 million</u></li> <li>Development costs for EMR for acute care hospitals: <u>Approximately JPY 50 million</u></li> </ul>	•	opera Acqui GCM sales)
owth	<ul> <li>Continued downtrend in ratio of companywide expenses to sales</li> </ul>	•	Hiring



### \*new updates in red

### **Progress/Update**

sed our sales forecast due to ter-than-expected earnings gress

ed our EBITDA margin cast on improvement in gins

ted generating revenues in the but see large room to improve rational efficiency isition and consolidation of Co., Ltd. (negligible impact on


ng proceeding according to plan

New Services

# GCM Co., Ltd. Acquisition

At the Board of Directors Meeting held on July 20, 2023, we decided to acquire GCM Co., Ltd (GCM). GCM operates a factoring business for medical institutions and nursing care facilities and we plan to drive synergies by leveraging technology and our customer base.

Main business	Factoring business
Established	April 2013
Annual net sales	JPY 117 million FY9/2022



- opening a new business, etc.

### **MEDLEY**

 Under our mission of "Creating the future of medical" healthcare" this acquisition will complement our existing business by resolving funding issues for medical institutions and nursing care facilities

• Given we will leverage technology to achieve synergies described below, we include to in the New Services

• Impact to FY2023 earnings will be negligible as GCM

- Automating and streamlining funding operations - Consider integration with our existing services

# 1. FY2023 Q2 Results

2. Progress Towards Mid-Term Targets and FY2023 Forecast

# 3. Investment Highlights



# **Investment Highlights**

# 1. Vast opportunities in the medical and healthcare field

# 2. Continuous growth through maximization of customer office numbers and ARPU

3. Disciplined investment in growth



30 Copyright© Medley, Inc. ALL RIGHTS RESERVED.

### 1. Market

Technology is not being fully leveraged in the medical and healthcare industry due to heavy regulations. Our ultimate goal is to solve medical and healthcare issues by leveraging the internet and information technology.

### HR PF Business

We operate JobMedley, one of Japan's largest recruitment systems in medical healthcare field, and JobMedley academy, online video nursing training service. Our objective is not only to provide better matching for job seekers and medical providers, but to resolve the shortage of medical and healthcare personnel by facilitating unemployed but qualified workers return to work and tackling the issue of uneven service distribution between communities.




### **New Services**

We are continuously developing businesses to promote the use of IT in the nursing care area and in peripheral areas.


### Medical PF Business

We provide CLINICS telemedicine, one of the leading telemedicine system in Japan, CLINICS electronic medical record system (EMR) for clinics, Pharms (cloud-based pharmacy support system) for pharmacies, MEDLEY (online medical encyclopedia dedicated for patients), MALL (EMR for hospitals), and Dentis (cloud-based dental clinic support system) with a focus to build a platform beneficial for both patients and medical institutions.










### **MEDLEY**

Medical institutions in Japan have been facing a variety of challenges including heavy burden on-site and increased complexity of medical care. The importance of digitalization is increasing owing to macro trends such as the declining birthrate and aging population and advancements in digital technologies.



# **Digitalization Essential to Medical and Healthcare Industry**



### Government

### **Financial stringency**

• Massive social welfare spending



### **Optimal Allocation of Resources by Government**

### 1. Market

# **Defensive Growth Industry: Social Welfare Spending and Number of Employees Not Impacted by Economic Trends**

Spending on social welfare is expected to rise continuously in Japan owing to the aging of the population. The number of medical care workers taking care of elderly patients is also expected to rise.


**Social Welfare Spending Forecast**<sup>(1)</sup>



Nursing care cost Medical cost




(1) Report from Ministry of Health, Labour and Welfare







The Japanese medical industry suffers from a chronic shortage of workers, with a jobs-to-applicant ratio that remains much higher than the average for all industries regardless of economic conditions. We estimate the current market size to be approximately JPY 370 billion, and expect expansion to up to JPY 430 billion in 2025 driven by increasing demand.



(1) Ministry of Health, Labour and Welfare statistics, 3-months average

1. Market

# Stable, High Demand in the Medical / Healthcare Industry

(2) Estimates by Medley, Inc.

FY2021A: Calculated based on the number of employees in the medical/beauty healthcare industries in Japan (roughly 9.9 million), the average annual hiring rate for occupations that fall under the category of "medical care/ welfare" and "environmental health services" in FY2019 employment trend survey results (approximately 16% for the "medical care/welfare", approximately 25% for the "environmental health services" = approximately 1.6 million people), and the average unit price of JobMedley placements for all occupation categories. FY2025E: Based on the abovementioned FY2021A multiplied by the medical cost growth rate in Future Outlook for Social Security in Anticipation of 2040 published by the Cabinet Secretariat, the Cabinet Office, the Ministry of Finance, and the Ministry of Health, Labour and Welfare. Copyright© Medley, Inc. ALL RIGHTS RESERVED.



### 1. Market

# Vast Opportunities in Cloud-based Medical IT System Market

The estimated current medical IT system market size is approximately JPY 470 billion. Today, the bulk of the systems used in medical industry are on-premises based (on-site servers), but more platforms have been adopting cloud-based systems since the deregulation in 2010, owing to advantages in terms of costs and convenience. Due to the low operating efficiency and customary use of long-term contracts, 10-year (FY2020-2030) CAGR in target operating area of the cloud medical IT system market is expected to be 12.9%.

### Scale of the Medical IT System Market<sup>(1)</sup>

### **Cloud Medical IT System**

(Telemedicine, Online drug administration, **Cloud-based EMR, Reservation system for** treatment and examination)


### JPY **13.5** billion

Others JPY 183.5 billion

> Medical IT System Market (**2020** actual) JPY 467.5 billion

### Currently, most systems are on-premises based (on-site servers)

(1) The Current Status and Future Market Trends Related to Medical Cooperation and Medical Platforms in 2022 by Fuji Keizai



Cloud-based systems are expected to become more prevalent in light of deregulation, cost advantages, and greater convenience.



1. Market

### **COVID-19 Accelerated to Deregulation and Policies to Digital Utilization MEDLEY**

While COVID-19 has increased consumer awareness and behavior toward digital utilization, it has also revealed a delay in the digital utilization of healthcare. In response, the government has announced and implemented deregulations and policies related to the promotion of online medical services and electronic medical records and the revitalization of regional healthcare through digital utilization, which we believe will be a tailwind for our business development.

Institution/Policy	Overview	Major medical a
The Revision of Official Medical Fees in 2022	<ul> <li>Implemented on April 1, 2022</li> <li>Large-scale deregulation of telemedicine and Online drug administration</li> <li>Promoting digital utilization in the dental field</li> </ul>	<ul> <li>Increase in points assigned to initial examinations (treatment)</li> <li>Changes to calculation requirements for online drug <ul> <li>Calculation requirements for online drug adminis</li> <li>"patients receiving prescriptions via telemedicine</li> </ul> </li> <li>Addition of item related to "follow up" to requirement</li> <li>Additional points for home dental care using telecoment</li> </ul>
Basic Policy on Economic and Fiscal Management and Reform 2022 (The Basic Policy 2022 <sup>(1)</sup> )	<ul> <li>Cabinet decision on June 7, 2022</li> <li>Basic economic policy of Kishida Cabinet         <ul> <li>Fiscal policy, and investment in human resources, green procurement, digitalization, etc. to achieve the concept of "New Form of Capitalism"</li> </ul> </li> <li>Promoting medical DX as a priority investment         <ul> <li>Established "Headquarters for Medical Digital Transformation (DX) Promotion" on October 12, 2022</li> </ul> </li> </ul>	<ul> <li>Creation of a national medical data platform <ul> <li>Sharing and exchanging information using "On</li> </ul> </li> <li>Promoting standardization and implementation of <ul> <li>Utilization of a medical informatization support</li> </ul> </li> <li>Promoting DX related of medical fee revision <ul> <li>Streamlining for revision and the related of offi</li> </ul> </li> </ul>
Vision for a Digital Garden City Nation <sup>(2)</sup>	<ul> <li>Cabinet decision on June 7, 2022</li> <li>Realize new rural environments nationwide that are both convenient and attractive while maintaining their prosperity <ul> <li>Aggressive promotion of DX in rural areas in both the public and private sectors by building digital infrastructure quickly</li> <li>The government provides grants to local governments</li> <li>Healthcare is an important theme for " building an attractive community"</li> </ul> </li> </ul>	<ul> <li>Community revitalization through disease prevention         <ul> <li>Improving the environment for the development</li> </ul> </li> <li>Use of future technologies in the medical field         <ul> <li>Use of future technologies in the medical field</li> <li>Use of future technologies in the medical field telemedicine)</li> <li>The spread and promotion of online drug admining</li> <li>Pushing for using electronic prescription and on</li> </ul> </li> </ul>
Medical DX roadmap	<ul> <li>As indicated in the Basic Policy 2022 published by the Headquarters for Medical Digital Transformation (DX) Promotion on June 2, 2023         <ul> <li>Driving medical/healthcare-related policies stated in the Basic Policy 2022</li> </ul> </li> </ul>	<ul> <li>Creation of a nationwide medical data platform <ul> <li>Creation of an EMR data sharing system (tental</li> <li>Data sharing using My Number card</li> </ul> </li> <li>Standardization of EMR information <ul> <li>Start development of a standardized EMR (in F)</li> <li>Targeting to have almost all medical institution</li> </ul> </li> </ul>

- (1) The Kishida Cabinet's Basic Policy on Economic and Fiscal Management and Reform 2022 Reference: https://japan.kantei.go.jp/ongoingtopics/kishida\_basic\_policy.html (2) Prime Minister Kishida's policy concept Reference: https://www.japan.go.jp/kizuna/\_userdata/pdf/2022/spring2022/vision\_for\_a\_digital\_garden\_city\_nation.pdf

### affairs

(to just under 90% of face-to-face medical

administration guidance

nistration guidance is no longer limited to ne systems"

ents for drug administration guidance fees ommunication devices

On-line qualification confirmation" system of EMRs ort fund

fficial medical fees

tion and promotion of health promotion ent of PHR services, etc.

Id (Proper spread and promotion of

ministration on-line qualification confirmation, etc.


ntative name)

FY2024)

ons adopt an EMR system by 2030

Starting in 2020, large-scale deregulation was implemented as a temporary measure in response to COVID-19. <u>Further</u> <u>deregulation was implemented along with the revision to official medical fees in 2022.</u>

> Medical fees for telemedicine, online medical management, and online home healthcare were newly established as part of the 2018 revision of medical service fees. "Guidelines for the proper implementation of telemedicine" was also announced and the government imposed strict restrictions on telemedicine



# (Ref.) Changes in Japanese Telemedicine Regulations (illustrative)

Lifting of ban on telemedicine treatment for patients with chronic diseases receiving regular medical examinations

Feb 28, 2020

Partial revision of "Guidelines for the proper implementation of telemedicine"

Temporary lifting of ban on initial medical examinations via telemedicine system Apr 10, 2020

Mar 19, 2020 Lifting of ban on telemedicine treatment for patients with mild **COVID-19** symptoms


### Sep 2019

Ministry of Health, Labour and Welfare launches "Review meeting on Smooth **Operation of Electronic** Prescriptions"










2. Growth

# Maintain High Sales Growth by Maximizing Number of Customers and ARPU

Our management policy is to maximize long-term free cash flow and maintain high sales growth by increasing the value provided to our customers. In order to achieve continuous sales growth, we pursue a basic strategy of maximizing the number of customer offices served and improving ARPU. In order to continuously improve ARPU, we pursue a business model focused on stable, recurring sales.






LTM Sales and EBITDA trend 2. Growth

Although sales in HR PF tend to concentrate on every Q2, sales and EBITDA for the last 12 months (LTM) have been on a stable increasing trend.






(1) Sum of sales and EBITDA for the last 12 months from the end of each quarter. Figures for FY2021 and earlier are based on the new revenue recognition standard.



17,861 15,771 14,185 3,102 2,367 1<u>,91</u>9 Q4'22 Q1'23 Q2'23

In HR PF Business, in addition to shoring up our customer base and pool of registered workers, we conduct investments to develop and deliver new products while leveraging our customer base.



(1) Ministry of Health, Labour and Welfare, Ministry of Internal Affairs and Communications etc. statistics

# HR PF: Expanding Customer Base by Cost Leadership




### 2. Growth

# Medical PF: Improved ARPU via Synergy with HR PF Business **Customer Base**

Medical PF is currently focused on developing SaaS products and, in addition to leveraging the customer base of HR PF Business to expand the number of customer offices, we are improving ARPU by strengthening our product lineup.

### Maximize Number of Customers

- hospitals, clinics, pharmacies, and dental clinics
- base of HR PF Business



(1) Ministry of Health, Labour and Welfare statistics

### Improve ARPU






2. Growth

# Medical PF: Product Development Using Integrated Patient Database as a Core Technology

Many of the products provided by Medical PF Business use as a core technology our patient integration platform, which allows the sharing of medical data between different medical systems and applications used by patients (Japanese patent registration number 6921177).






### 3. Investment

# **Continued Disciplined Investment in Growth**

In order to reach our mid-term targets ahead of schedule, we will aggressively invest capital secured via operating cash flow and interest-bearing debt in our businesses. We will also conduct M&A while keeping the company EBITDA positive on a companywide basis.



### MEDLEY

Establish target timetable for bringing lossmaking businesses into the black and systematically increase operating cash flow

• Take full advantage of financing opportunities presented by very low interest rates in Japan and our business model focused on stable.

• Equity financing will be conducted based on factors such as our share price, market conditions, and whether it is necessary to procure capital in order to reach our mid-term

# A: Investment in Growth Targeting Maximization of Customer Numbers and Improvement of ARPU

We aggressively invest capital secured via operating cash flow and interest-bearing debt while keeping the group-wide EBITDA positive.


## Investment in Businesses

### Aggressive investment while maintaining group-wide profitability

Focus on achieving cost merits on a pretax investment basis while also focusing on after-tax capital base strengthening merits

### Focus on sound unit economics

- Confirm investment return periods and LTV/CAC for • all businesses
- Determine profitability timing and invest aggressively in businesses with sound unit economics



other companies



Copyright© Medley, Inc. ALL RIGHTS RESERVED.

3. Investment

# **B:** Promoting Digitalization in the Healthcare Sector Through Synergy-Focused M&A

We view M&A as an important growth driver. Our group companies will work together to promote digitalization by focusing on creating synergies utilizing our robust customer base in the healthcare sector.



(1) As of end of June 2023



### **B: Overview of Completed M&A** 3. Investment

We must develop a wide range of systems in order to achieve our mission of "Creating the future of medical healthcare" wherein patients are able to make full use of medical care, medical institutions are efficiently managed, and governments are able to optimally allocate medical resources. We plan to expand our businesses through both in-house development and M&A. Below, we provide an overview of completed M&A.

Name	Impacted segment	Time of grouping	Status
Tenxia	HR PF	Sep. 2022	<ul> <li>Initiatives to generate long-term synergies with recruitment system</li> <li>Integrated into Medley in February 2023</li> </ul>
NaCI MEDICAL	Medical PF	Mar. 2019	<ul> <li>Made progress in development of new cloud-based receipt computer an Medley</li> </ul>
Pacific Medical	Medical PF	Jan. 2021	<ul> <li>Strengthened sales and marketing of EMR systems to small- and media</li> <li>Leveraged existing assets to develop the MINET group management sy to assist with regional medical cooperation</li> </ul>
MEDIPASS	HR PF/Medical PF / New Services	Feb. 2021	<ul> <li>Integrated online training business with Medley in January 2022, improve multilingual support</li> <li>Regarding other MEDiPASS businesses, withdrew from the staffing bus in some businesses in FY2022)</li> </ul>
Source code of dental receipt computer	Medical PF	Aug. 2019	<ul> <li>Leveraged knowhow to completely rebuild system assets acquired in 20 Dentis in January 2022</li> </ul>
Proof-of-concept testing base	Medical PF	Dec. 2020	<ul> <li>Ownership of facilities where proof-of-concept testing for Pharms syste contributed considerably to development of Pharms</li> <li>As facilities where proof-of-concept testing is conducted must serve as to retain ownership of other facilities formats</li> </ul>
<b>minacolor</b> *an equity method affiliate in the future	Medical PF	Oct. 2021	<ul> <li>Joint operation of businesses with NTT DOCOMO</li> <li>Steady expansion of business performance after becoming a group com</li> </ul>
Other	Medical PF	Jun. 2020	<ul> <li>Acquired knowhow and customer accounts by securing EMRs of other of completed</li> </ul>



and merged the company with

dium-sized hospitals system for medical corporations and

roved core functions, and developed

usinesses (sales expected to decline

2019 and released new system

stem for pharmacies was conducted

as models for the future, we consider

ompany


r companies. Partial transfer of EMRs

### 3. Investment

# C: Increase Operating Cash Flow by Making Lossmaking Businesses Profitable in Line with Our Plans

We have set target years for bringing lossmaking businesses into the black and will increase operating cash flow in line with our plans. In terms of Pharms, the timing of the turnaround was pushed back by one year due to delays in ARPU improvement. Cash generation phase: Positive operating cash flow Profitability phase: Operating cash flow negative, but unit economics sound (return on investment expected) Commercialization phase: Creation of business model targeting generation of operating cash flow, unit economics carefully monitored

Profitable in FY2022		
Cash generation phase		
<b>Job Medley</b> Expected to turn profitable in FY24		
CLINICS オンライン診療 Telemedicine system Turned Profitable in FY19 Expected to turn profitable in FY24		
EMR for hospitals		
<ul> <li>Investing to accelerate growth</li> </ul>		
Expected to turn profitable in FY23		








3. Investment

We set a high ratio of cash and deposits in order to make flexible investments. In addition to cash flow from operations, we have a strong financial base funded by equity offerings and by bank loans. Under the current circumstances, additional equity financing to achieve our mid-term targets is not required. We seek for appropriate use of capital as attractive investment opportunities are expected under market fluctuations.



### **MEDLEY**

Make appropriate use of debt whilst

Secure more LOC and increase borrowings to take advantage of business opportunities - May 2020: Long-term borrowings JPY 0.5 bn - November 2020: Long-term borrowings JPY 3.0 bn

Conducted JPY 5.4 bn public offering


Conducted JPY 5.1 bn third-party allotment

Repurchased JPY 1.8 bn of shares

(Ref.) **Business Overview** 

# HR PF: Success-fee-based Hiring Support System for Medical / Healthcare Industry

JobMedley is a recruitment system used by businesses (mainly medical institutions) in the nursing, childcare, and healthcare fields. Recruitment information for over 50 types of qualified professionals can be entered into the system and placement fee is charged when a placement is successfully made. The placement fee varies depending on the occupation type and hiring classification.





# Candidates




Database of qualified person in the medical/healthcare field with more than 50 occupations

(Ref.) **Business Overview** 

# HR PF: **Industry Has a Long-tail Structure:** Our Strengths Are in the Middle and Tail Segments

Out of the 10 million workers in the medical/beauty healthcare industry, 22% are doctors, nurses, and pharmacists, who are highly competitive in terms of job placement. On the other hand, there are few competitors in the remaining 78% - the middle and tail segments where we have captured a leading market share. We currently have over 1.7 million users in more than 50 occupations registered in our system.




(1) Ministry of Health, Labour and Welfare statistics

### **MEDLEY**

Dental technician Orthoptist 35k 10k Certified clinical Welfare equipment psychologist 72k consultant 34k Clinical engineer etc. 30k



JobMedley covers more than 50 different types of medical/healthcare occupations, and recruitment success fee is approximately 50 - 80% lower than the industry average. While many recruitment agencies conduct most of their business in person, JobMedley uses online support staff, thereby increasing efficiency and enabling lower fees.



# Low-cost Structure Gives Advantages in Terms of Pricing


(2) This refers to typical fees for recruitment services for occupations such as doctors, nurses, childcare professionals, physical therapists, dentists, and care workers among the 50 occupations we handle. (Some recruitment services employ different methods for setting success fee amounts that are different from that described above.)



## HR PF: **Building a Stable Customer Base with Repeat Customers**

We are building a stable customer base by encouraging customers to become repeat users of JobMedley. Recently acquired customers are making extensive use of our scouting functions. This has boosted the ratio of applicants per job offering and contributed to sales growth.






(Ref.)

Business

**Overview** 




(1) Based on per-customer monthly orders/sales value data.



(Ref.) Business **Overview** 

# **Medical PF: CLINICS/Pharms Earnings Models**

CLINICS and Pharms use earnings models wherein it receives system usage fees from medical institutions (CLINICS: clinics/ hospitals, Pharms: dispensing pharmacies). Usage fees include initial fees for installation and monthly fee payments. Patients can receive online medical experience from treatment to drug administration guidance via both systems and CLINICS app.




### Shipment of drugs



(Ref.) Company **Overview** 

Change in Ratio of Ownership


The ratio of institutional investors, mainly overseas institutional investors, accounts for 48% as of end-June 2023. We will continue to endeavor to provide robust disclosure that helps both institutional and individual long-term investors make investment decisions.





### (Ref.) Company **Overview**


# **Historical Share Price**





We prioritize issues to be addressed (materiality) in order to meet the expectations and demands of our stakeholders. Our materiality is determined based on issues directly related to our mission, "Creating the future of medical and healthcare". By working to solve these critical issues, we strive to continuously contribute to society while increasing enterprise value.

# **Creating the Future of Medical and Healthcare**



For more information, access our corporate website.

(Ref.) Company **Overview** 

# Identification of Materiality

### **MEDLEY**

### For government & communities

• Participation in proof-of-concept testing/information provision • Supports for disaster areas • Supports for infection prevention

### Strengthening of governance

• Strengthening of corporate



### Creating the Future of Medical and Healthcare